Search hospitals > Pennsylvania > Bethlehem
Saint Luke's University Hospital-Bethlehem Campus
Claim this profileBethlehem, Pennsylvania 18015
Global Leader in Melanoma
Global Leader in Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Lung Cancer
Conducts research for Pancreatic Cancer
209 reported clinical trials
19 medical researchers
Summary
Saint Luke's University Hospital-Bethlehem Campus is a medical facility located in Bethlehem, Pennsylvania. This center is recognized for care of Melanoma, Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer and other specialties. Saint Luke's University Hospital-Bethlehem Campus is involved with conducting 209 clinical trials across 330 conditions. There are 19 research doctors associated with this hospital, such as Melissa A. Wilson, Neil D. Belman, Darius Desai, and Gary Lu.Area of expertise
1Melanoma
Global LeaderStage IV
Stage III
BRAF positive
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Melissa A. WilsonSt. Lukes University Health Network10 years of reported clinical research
Studies Melanoma
Studies Cutaneous Melanoma
5 reported clinical trials
9 drugs studied
Neil D. BelmanSaint Luke's University Hospital-Bethlehem Campus11 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
8 drugs studied
Darius DesaiSt. Luke's University Health Network - Allentown Cancer Center4 years of reported clinical research
Studies Pancreatic Cancer
Studies Cancer
4 reported clinical trials
11 drugs studied
Gary LuSt. Lukes University Health Network6 years of reported clinical research
Studies Melanoma
Studies Cancer
4 reported clinical trials
11 drugs studied
Clinical Trials running at Saint Luke's University Hospital-Bethlehem Campus
Ovarian Cancer
Lung Cancer
Breast Cancer
Fallopian Tube Cancer
Pancreatic Cancer
Uterine Cancer
Peritoneal Cancer
Heart Attack
Brain Tumor
Breast cancer
Olaparib +/- Bevacizumab
for Ovarian Cancer
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Recruiting2 awards Phase 34 criteria
Minimally Invasive Surgery vs Laparotomy After Chemotherapy
for Ovarian and Related Cancers
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedure that uses small incision(s) and is intended to produce minimal blood loss and pain for the patient. Laparotomy is a surgical procedure which allows the doctors to remove some or all of the tumor and check if the disease has spread to other organs in the body. MIS may work the same or better than standard laparotomy after chemotherapy in prolonging the return of the disease and/or improving quality of life after surgery.
Recruiting2 awards Phase 39 criteria
Rina-S
for Ovarian Cancer
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Luke's University Hospital-Bethlehem Campus?
Saint Luke's University Hospital-Bethlehem Campus is a medical facility located in Bethlehem, Pennsylvania. This center is recognized for care of Melanoma, Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer and other specialties. Saint Luke's University Hospital-Bethlehem Campus is involved with conducting 209 clinical trials across 330 conditions. There are 19 research doctors associated with this hospital, such as Melissa A. Wilson, Neil D. Belman, Darius Desai, and Gary Lu.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.